147 related articles for article (PubMed ID: 19203724)
1. Pharmacokinetics and pharmacodynamic action of budesonide after buccal administration in healthy subjects and patients with oral chronic graft-versus-host disease.
Dilger K; Halter J; Bertz H; Lopez-Lazaro L; Gratwohl A; Finke J
Biol Blood Marrow Transplant; 2009 Mar; 15(3):336-43. PubMed ID: 19203724
[TBL] [Abstract][Full Text] [Related]
2. Effect of high-dose metronidazole on pharmacokinetics of oral budesonide and vice versa: a double drug interaction study.
Dilger K; Fux R; Röck D; Mörike K; Gleiter CH
J Clin Pharmacol; 2007 Dec; 47(12):1532-9. PubMed ID: 18048573
[TBL] [Abstract][Full Text] [Related]
3. The effect of budesonide mouthwash on oral chronic graft versus host disease.
Sari I; Altuntas F; Kocyigit I; Sisman Y; Eser B; Unal A; Fen T; Ferahbas A; Ozturk A; Unal A; Cetin M
Am J Hematol; 2007 May; 82(5):349-56. PubMed ID: 17109390
[TBL] [Abstract][Full Text] [Related]
4. No relevant effect of ursodeoxycholic acid on cytochrome P450 3A metabolism in primary biliary cirrhosis.
Dilger K; Denk A; Heeg MH; Beuers U
Hepatology; 2005 Mar; 41(3):595-602. PubMed ID: 15726657
[TBL] [Abstract][Full Text] [Related]
5. Active eosinophilic esophagitis is associated with impaired elimination of budesonide by cytochrome P450 3A enzymes.
Dilger K; Lopez-Lazaro L; Marx C; Bussmann C; Straumann A
Digestion; 2013; 87(2):110-7. PubMed ID: 23364258
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics and pharmacodynamic action of budesonide in children with Crohn's disease.
Dilger K; Alberer M; Busch A; Enninger A; Behrens R; Koletzko S; Stern M; Beckmann C; Gleiter CH
Aliment Pharmacol Ther; 2006 Feb; 23(3):387-96. PubMed ID: 16422998
[TBL] [Abstract][Full Text] [Related]
7. Improvement in oral chronic graft-versus-host disease with the administration of effervescent tablets of topical budesonide-an open, randomized, multicenter study.
Elad S; Zeevi I; Finke J; Koldehoff M; Schwerdtfeger R; Wolff D; Mohrbacher R; Levitt M; Greinwald R; Shapira MY
Biol Blood Marrow Transplant; 2012 Jan; 18(1):134-40. PubMed ID: 21703973
[TBL] [Abstract][Full Text] [Related]
8. Budesonide: a novel treatment for oral chronic graft versus host disease.
Elad S; Or R; Garfunkel AA; Shapira MY
Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2003 Mar; 95(3):308-11. PubMed ID: 12627101
[TBL] [Abstract][Full Text] [Related]
9. Effect of an oral contraceptive on the plasma levels of budesonide and prednisolone and the influence on plasma cortisol.
Seidegård J; Simonsson M; Edsbäcker S
Clin Pharmacol Ther; 2000 Apr; 67(4):373-81. PubMed ID: 10801246
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics and pharmacodynamic action of budesonide in early- and late-stage primary biliary cirrhosis.
Hempfling W; Grunhage F; Dilger K; Reichel C; Beuers U; Sauerbruch T
Hepatology; 2003 Jul; 38(1):196-202. PubMed ID: 12830002
[TBL] [Abstract][Full Text] [Related]
11. Grapefruit juice interaction with oral budesonide: equal effect on immediate-release and delayed-release formulations.
Seidegård J; Randvall G; Nyberg L; Borgå O
Pharmazie; 2009 Jul; 64(7):461-5. PubMed ID: 19694184
[TBL] [Abstract][Full Text] [Related]
12. Enteral budesonide in treatment for mild and moderate gastrointestinal chronic GVHD.
Andree H; Hilgendorf I; Leithaeuser M; Junghanss C; Holzhueter S; Loddenkemper C; Steiner B; Freund M; Wolff D
Bone Marrow Transplant; 2008 Oct; 42(8):541-6. PubMed ID: 18641680
[TBL] [Abstract][Full Text] [Related]
13. Multidrug resistance 1 genotype and disposition of budesonide in early primary biliary cirrhosis.
Dilger K; Cascorbi I; Grünhage F; Hohenester S; Sauerbruch T; Beuers U
Liver Int; 2006 Apr; 26(3):285-90. PubMed ID: 16584389
[TBL] [Abstract][Full Text] [Related]
14. Formulation of budesonide mouthwash for the treatment of oral chronic graft-versus-host disease.
Van Schandevyl G; Bauters T
J Oncol Pharm Pract; 2016 Feb; 22(1):82-5. PubMed ID: 25411262
[TBL] [Abstract][Full Text] [Related]
15. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
Brandi L
Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
[TBL] [Abstract][Full Text] [Related]
16. Oral budesonide in the management of Crohn's disease.
Hofer KN
Ann Pharmacother; 2003 Oct; 37(10):1457-64. PubMed ID: 14519035
[TBL] [Abstract][Full Text] [Related]
17. Effects of liver fibrosis on verapamil pharmacokinetics in rats.
Chen M; Xu D; Hu XL; Wang H
Clin Exp Pharmacol Physiol; 2008 Mar; 35(3):287-94. PubMed ID: 17973928
[TBL] [Abstract][Full Text] [Related]
18. Presystemic elimination of budesonide in man when administered locally at different levels in the gut, with and without local inhibition by ketoconazole.
Seidegård J; Nyberg L; Borgå O
Eur J Pharm Sci; 2008 Nov; 35(4):264-70. PubMed ID: 18706998
[TBL] [Abstract][Full Text] [Related]
19. Bioavailability and metabolism of prochlorperazine administered via the buccal and oral delivery route.
Finn A; Collins J; Voyksner R; Lindley C
J Clin Pharmacol; 2005 Dec; 45(12):1383-90. PubMed ID: 16291713
[TBL] [Abstract][Full Text] [Related]
20. Mechanism-based PK/PD model for the lymphocytopenia induced by endogenous and exogenous corticosteroids.
Meibohm B; Derendorf H; Möllmann H; Fröhlich P; Tromm A; Wagner M; Homrighausen S; Krieg M; Hochhaus G
Int J Clin Pharmacol Ther; 1999 Aug; 37(8):367-76. PubMed ID: 10475139
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
